Chronic Fatigue Syndrome: The Current Status and Future Potentials of Emerging Biomarkers.

IF 2.2 Q3 MEDICINE, RESEARCH & EXPERIMENTAL

Fatigue-Biomedicine Health and Behavior Pub Date : 2014-06-01 DOI:10.1080/21641846.2014.906066

David Benjamin Fischer, Arsani Hany William, Adam Campbell Strauss, Elizabeth R Unger, Leonard Jason, Gailen D Marshall, Jordan D Dimitrakoff

{"title":"Chronic Fatigue Syndrome: The Current Status and Future Potentials of Emerging Biomarkers.","authors":"David Benjamin Fischer, Arsani Hany William, Adam Campbell Strauss, Elizabeth R Unger, Leonard Jason, Gailen D Marshall, Jordan D Dimitrakoff","doi":"10.1080/21641846.2014.906066","DOIUrl":null,"url":null,"abstract":"<p><p>Chronic fatigue syndrome (CFS) remains an incompletely characterized illness, in part due to controversy regarding its definition, biological basis and diagnosis. Biomarkers are objective measures that may lead to improvements in our understanding of CFS by providing a more coherent and consistent approach to study, diagnosis and treatment of the illness. Such metrics may allow us to distinguish between CFS subtypes - each defined by characteristic biomarkers - currently conflated under the single, heterogeneous condition of CFS. These delineations, in turn, may guide more granular, focused, and targeted treatment strategies based on more precise characterizations of the illness. Here, we review potential CFS biomarkers related to neurological and immunological components of the illness, and discuss how these biomarkers may be used to move the field of CFS forward, emphasizing clinical utility and potential routes of future research.</p>","PeriodicalId":44745,"journal":{"name":"Fatigue-Biomedicine Health and Behavior","volume":"2 2","pages":"93-109"},"PeriodicalIF":2.2000,"publicationDate":"2014-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/21641846.2014.906066","citationCount":"32","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Fatigue-Biomedicine Health and Behavior","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/21641846.2014.906066","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 32

Abstract

Chronic fatigue syndrome (CFS) remains an incompletely characterized illness, in part due to controversy regarding its definition, biological basis and diagnosis. Biomarkers are objective measures that may lead to improvements in our understanding of CFS by providing a more coherent and consistent approach to study, diagnosis and treatment of the illness. Such metrics may allow us to distinguish between CFS subtypes - each defined by characteristic biomarkers - currently conflated under the single, heterogeneous condition of CFS. These delineations, in turn, may guide more granular, focused, and targeted treatment strategies based on more precise characterizations of the illness. Here, we review potential CFS biomarkers related to neurological and immunological components of the illness, and discuss how these biomarkers may be used to move the field of CFS forward, emphasizing clinical utility and potential routes of future research.

查看原文本刊更多论文

慢性疲劳综合征:新兴生物标志物的现状和未来潜力。

慢性疲劳综合征(CFS)仍然是一种特征不完全的疾病，部分原因是由于其定义、生物学基础和诊断存在争议。生物标志物是一种客观的测量方法，可以通过提供更连贯和一致的方法来研究、诊断和治疗慢性疲劳综合症，从而提高我们对慢性疲劳综合症的理解。这样的指标可以让我们区分CFS亚型-每个亚型都由特征生物标志物定义-目前在CFS的单一，异质性条件下合并。这些描述反过来可以指导基于更精确的疾病特征的更细化、更集中和更有针对性的治疗策略。在此，我们回顾了与该疾病的神经和免疫学成分相关的潜在CFS生物标志物，并讨论了如何利用这些生物标志物推动CFS领域的发展，强调了临床应用和未来研究的潜在途径。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Fatigue-Biomedicine Health and Behavior MEDICINE, RESEARCH & EXPERIMENTAL-

CiteScore

5.20

自引率

7.10%

发文量

期刊介绍： Fatigue: Biomedicine, Health and Behavior is an international, interdisciplinary journal that addresses the symptom of fatigue in medical illnesses, behavioral disorders, and specific environmental conditions. These broadly conceived domains, all housed in one journal, are intended to advance research on causation, pathophysiology, assessment, and treatment. The list of topics covered in Fatigue will include fatigue in diseases including cancer, autoimmune diseases, multiple sclerosis, pain conditions, mood disorders, and circulatory diseases. The journal will also publish papers on chronic fatigue syndrome, fibromyalgia and related illnesses. In addition, submissions on specific issues involving fatigue in sleep, aging, exercise and sport, and occupations are welcomed. More generally, the journal will publish on the biology, physiology and psychosocial aspects of fatigue. The Editor also welcomes new topics such as clinical fatigue education in medical schools and public health policy with respect to fatigue.